Drug Detail

Information about Vatalanib

Generic Name	Vatalanib
IND	PTK787
Brand Name (US)
Manufacturer	Novartis
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 3
Indications
Overall Strategy	KIT Protein Based
Strategy	Block KIT + Block blood vessel growth
Drug Category	KIT/PDGFRA inhibitor+ VEGF inhibitor (antibody)

Vatalanib is a potent inhibitor of all known VEGFR tyrosine kinases and is active in the submicromolar range. It also inhibits other kinases, such as platelet-derived growth factor receptor beta (PDGFR-β) and c-Kit tyrosine kinase, but at higher concentrations.
PTK787 is also known as PTK787/ZK222584